Effects of Traditional Chinese Medicine on Chemotherapy-Induced Myelosuppression and Febrile Neutropenia in Breast Cancer Patients

Table 3

Multivariate analysis of clinicopathological variables of leukopenia.

Variables	Before propensity matching			After propensity matching
	OR	95% CI		OR	95% CI
Age	0.989	0.971–1.006	0.199	0.979	0.965–0.994	0.005
Chemotherapy regimens
1	1	—	—	1	—	—
2	0.976	0.539–1.765	0.935	0.773	0.468–1.274	0.312
3	4.477	2.764–7.251	<0.0001	3.208	2.228–4.617	<0.0001
4	1.552	0.942–2.558	0.085	1.251	0.837–1.869	0.275
TNM stage
I	1	—	—	1	—	—
II	1.227	0.858–1.756	0.262	1.360	1.014–1.823	0.040
III and IV	2.436	1.362–4.357	0.003	1.953	1.215–3.141	0.006
Neoadjuvant chemotherapy	0.788	0.476–1.304	0.354	0.584	0.377–0.905	0.016
ER	1.165	0.655–2.071	0.603	1.215	0.772–1.913	0.399
PR	0.781	0.457–1.333	0.364	1.003	0.654–1.537	0.989
HER-2	0.857	0.561–1.307	0.473	1.094	0.762–1.572	0.626
Ki67	1.132	0.791–1.620	0.499	1.552	1.163–2.071	0.003
TCM treatment	0.252	0.172–0.367	<0.0001	0.285	0.218–0.373	<0.0001

Chemotherapy: 1: the chemotherapy regimens contain AC/EC (Adriamycin or epirubicin, Cyclophosphamide) and CAF/CEF (Adriamycin or epirubicin, Cyclophosphamide, and 5-Fluorouracil). 2: the chemotherapy regimens contain TC (paclitaxel or docetaxel, Cyclophosphamide) and T (paclitaxel or docetaxel). 3: the chemotherapy regimens contain anthracyclines combined with paclitaxel or docetaxel: TAC/TEC (paclitaxel or docetaxel, Cyclophosphamide, and Adriamycin or epirubicin); TA/TE (paclitaxel or docetaxel, Adriamycin or epirubicin). 4: the chemotherapy regimens contain anthracyclines followed by paclitaxel or docetaxel: AC/EC (Adriamycin or epirubicin, Cyclophosphamide); CAF/CEF (Adriamycin or epirubicin, Cyclophosphamide, and 5-Fluorouracil), followed with T or TH (paclitaxel or docetaxel, Herceptin).